It effectively suppresses CD47 activation by targeting TSP-1, and reprograms highly vascularized ovarian tumors into poorly angiogenic ones, while concurrently activating anti-tumor immunity (Jeanne et al., 2021). The gene discussed is THBS1; the disease is neoplasm.